RFAI · RF Acquisition Corp II
AI read · Neutral
The AI's read
Shareholders approved RF Acquisition's merger with Singapore AI drug-discovery firm Nanyang Biologics, per recent SEC filings. That paves the way for the combined entity to list as NYB Holdings. The market already roared: RFAI jumped roughly 283% and hit a new 52-week high in premarket action. At the same time holders filed preliminary redemptions of 3,956,323 shares, which can still change before closing. Bottom line: the item is clearly bullish on fundamentals but largely priced in by a massive gap move, so headline upside is limited. We lean NEUTRAL and will watch final redemption figures and Nasdaq-listing confirmations for a fresh edge.